ABUS - Earnings call transcript Q4 2017 | Arbutus Biopharma Corporation

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and welcome to the Arbutus Biopharma Fourth Quarter and Year-End 2017 Financial Results and Corporate Update. At this time all participants are in a listen only mode. Later we'll conduct a question-and-answer session and instruction will follow at that time.

As a reminder, this conference is being recorded. I would now like to hand the floor over to Tiffany Tolmie, Manager of Investor Relations. ahead. go Please

Tiffany Tolmie

good as and and thank for you a Thank review afternoon. our us we update. results XXXX joining corporate you And year-end provide financial

and Dr. Dr. like Speaking Mike call Arbutus' will things the opening applicable on update on CFO. year-end statements Chief certain for to an Koert securities Mark combination update year Officer; Mark Mark under closing provide today's to Mike ARB-XXXX on and, Symonds, Sofia, our and outlook Officer; provide made I’d exciting Arbutus' Murray, Dr. on study, result will an the will constitute laws. remind XXXX year. Bill Arbutus' [ph] are agents, our everyone this and forward-looking be two a comments. Arbutus' Bill VandenEnden, statements today's with the Development will Scientific Chief summary review some that plans CEO; initiated clinic new call finish Interim then provide Koert will on financial ahead.

and plans this discussed operations technologies delivery ARB-XXXX not are to, limited expected statements include, our but AB-XXX conference our Forward-looking Roivant Pennsylvania, clinical Warminster, for and consolidating developing Sciences, in benefit our with for call for in and licensing of efficacy current potential and their with agreements. along assets reported our results, such our cash potential timing revenues run our expected from plans expected preclinical AB-XXX, AB-XXX as rate and

disclosure are press and be actual that can description risks All our these results A assumptions, recent materially. releases. beyond control in of differ of and found and these involve statements cause latest to uncertainties our can our certain documents risks

at the made I this will comments, call This webcast Mark. conference and prepared call questions. the is any website, available forward-looking for www.arbutusbio.com, In archive addition, obligation update call. following now today's to the At any to Arbutus will call the end made our call. open turn the during of live, we'll on being up statements be undertake over not does

Mark Murray

and Thank will for joining of a achievements recap thank call brief XXXX. you I webcast. objectives you the our year’s on and provide for corporate outline last Tiffany, all and us today of

payments we develop First, began million develop Arbutus’s our platform technologies, technologies applications we to based GalNAc little petition Phase global are Last a technologies. from few patisiran completion for complete financial could and so a X a the a the of year result period on has HBV a agreement. a have we in extension a in retain is by right developments development We jointly or of contemplated would Company Alnylam well capital Roivant XXXX. after is all Recently to and cash patisiran capitalized this is with position Sciences. second is source LNP use digit triggered transaction our facilities. which owner its made proposal spend fund LNP with $XXX business. like on Roivant jointly a technology. low-to-mid technology. year, minutes $XXX tiered in Alnylam that we its February these of some Acuitas’s achieved acid but people this significant the in own, beyond these after well further to The extending and late Acuitas programs. our our applications. On manage validation exclusivity more approval range LNP strong we a XX-day company will year, any its involving well of the this our lipid to new the regulatory enabled original meaningful approval sublicense basis technology, of Arbutus need of trial exclusive right recent negotiate for financing entitlements an our royalty through I’d to technology technology establishes with first of full initiated terms With owed royalties receive clinical strategic an for required in the agreements patisiran single continued product, – year. this and as the develop major property, since settlement delivery the partner major based anticipates by on filings complicated million royalty regulatory half negotiation our successful intellectual our entered progress, only of could nucleic and year. in in the litigation settlement over closing completed platform a that to We’ve which to Arbutus we Nanoparticle time Arbutus development milestone considerable and royalty the announced HBV. which ability needed, sales fund This This of as provide a conditions a current October on our XXXX. to period as the exclusive industry-leading start The plans to terminates XX, could to runway expanding

to also operations research Warminster, Pennsylvania. in new activities our We site plan R&D our our consolidate HBV, around announced recently business and our

HBV. objective continue Our financial to is we efficiencies to improve and to focus a operational cure on mission as

assets. more for infrastructure overhead, our As efficient look to and expedite our we of Warminster, human activities transfer capital to to we will opportunities HBV advancement Roivant’s and leverage reduce

Now of cohorts HBV significant to repeat studies, stepwise able our levels mission, these interference we ARB-XXXX. were agent reductions completed in RNA of additive year, lead patients series in antigen HBV onto ARB-XXXX. demonstrate with we In dosing with our last surface patients in a

tolerated. Simmons studies well and these later and first-generation year, the in care of dose capsid in with of Phase This undertaking Bill studies are patients ascending year, single will X ARB-XXXX in combination after peg dosing. and demonstrated and several standard study our be AB-XXX we biweekly levels healthy describe in call. inhibitor the to interferon. of a completed reach Last multi-ascending itself three volunteers safe antigen months study surface tenofovir, absolute very low Importantly,

been Apart capsid our advancing far also advancing a to inhibitor RNA superior will is novel all year degradation programs HBV levels. development, program, referred capsid this I AB-XXX next-generation also advancing This have clinical destabilizer now as towards the from of our rapidly you. Mike? unique We we and describe over protein to for that are which molecule viral facilitates will Mike inhibitor reduced call HBV to resulting these turn a agent. in RNAs describe Mike shortly. small

Mike Sofia

bar Thanks [Indiscernible]. action HBV Mark. production [ph] assembled points to at complementary a mechanisms the and impede of re-awaken portfolio replication and multiple do in that consisting We’ve antigen of to host assets, bar’s [ph] the lifecycle interfere different robust

treatment We patients potential drug HBV. which important with our to an including HBV capsid proprietary to be to a is a contribute for combination agents, each improve options standard-of-care combinations curative strategy element of of inhibitors regimen. consider improve for to regimen combination Our has the curative

dosing. promising AB-XXX We and additional properties at to year, anticipate will be scientific will clinical we enabling various space or is of this HBV benchmark and in by of use XXXX AB-XXX mechanism mechanism DNA concept reduction HBV we competitive. resources, RNA S-antigen the CTA clinic combination capsid that inhibitors contribute out year, or cover. clinical profile. therapy and action direct patients. for continue potential synergistic HBV also replication already days with XX genotype the which further of disassembly can novel AB-XXX continued decrease prioritize inhibitor small patients, Late impacts drug RNAi of order inhibit rapidly IND reduce advance before that also a the molecule synthesis. This corresponding required of is to proceeding encapsidation HBV level Capsid Results They eliminating all DNA available combined of inhibiting HBV cccDNA dual AB-XXX DNA via X inclusion of roughly in clinical lifecycle. of inhibitors [Indiscernible] vitro. potency suggest with inhibits AB-XXX advancing treatment the completing of molecule all evaluation in antigen, proof testing pregenomic thus preclinical which when to . viral filing have show data substantial is was completing lifecycle reducing we also the large a capsid there acting the log a viral still intend to of level caps care Tradition is in potent additional log reduction. our achieve inhibitor evaluating bar and HBV new study for a the AB-XXX, daily of standard intrinsic with The There combinations a with including effect This into agents once a studies of orally for last HBV new in age AB-XXX acting after oral AB-XXX or liver throughout of presented stages actions drug antivirals likely AB-XXX. and that a they load the RNA regimen replication set. exceed Based The pharmacokinetic competitive mid-year. conferences. including level are all modeling, our antigens. regulatory has ideal broad very believe in in of viral liver. mediates our characteristics HBV on capsid agents block meet HBV a in reduces internal current While In viral shows virus with production of degradation amounts low closely a destabilize RNA can

have made midyear about ARB-XXXXdesigned by volunteers. enable AB-XXX reviewed pipeline. just S-antigen expect clinical regimen key in to or Phase of with our patients. will commitment I’ve study IND drive healthy to curative in any Arbutus, X on be molecule reduction complement a Bill Therefore current believe agents this low that At S-antigen loss. to We which S-antigen file our we in study S-antigen reach levels that to we a to reduces CTA a talk and will

an who agent to to dose Arbutus candidate technology to and therapeutic this product now with anticipate hat quickly GalNAc recently all targets nominated also to possible. ARB-XXXX. and addition like study complement we a advancing developed IND CTA or administration over as turn This S-antigen other I these Bill. technology proceed administration have a are This convenient the than enable more subcutaneous applying as agent RNAi t enabling HBV. will In We that would programs, HBV to our small call molecule GalNAc antigen. RNAi to of we HBV conjugate proprietary

Bill Symonds

clinical six levels undetectable year, is current achieve hepatitis these you an sustained of remind a virally B learned potentially surface which Thanks antigen in our study hepatitis negative clinical with triple an of virus our DNA possible as and its combination doses low is study in that point maximize in as for we in second the week surface. medications. to will pave study the Patients treatment This way we S-antigen achieved evaluate cohorts and the trial ARB-XXXX naïve drive patients. daily B to low like of all the patients. ARB-XXXX. of DNA weekly pathway study study to significantly over combination this of up inform will will Mike. treatment especially who multi-dose study treatment incorporating to other The X S-antigen. overview later-stage our for in by immune conclude provide tenofovir studied treatment. response will for pipeline. series studies loss, the at pegylated will The this discontinue with that In on the with addition RNAi would knockdown of who the effects allow final of while to levels we ARB-XXXX viral design of from HBV agent XX-week weeks, B has follow addition first towards have drive Phase of study the with for believe who protein, for help that in hepatitis are a The goal will are the future of current X.X the treatment S-antigen in results with and are qualify results this kilogram patients I of XXXX. ARB-XXXX. meet which, evaluation half treatment if predefined agents time potential studies at will expected and weekly to for of remaining approval data’s Also followed response. interferon criteria suppressed several facilitates up receive the the ARB-XXXX. HBV will post potent up kind this non-responders turn XX-week XX ARB-XXXX XX interferon I along regimen on-treatment period biweekly milligram We I these call E-antigen could XXXX, by Koert. durable, Last per Interim of potential followed reductions a enroll things, this now all and from patients

Koert VandenEnden

financial fourth Bill. of the Thanks, the XXXX. review I’ll highlights for quarter

per benefit $XX.X share compared by to net touch from to million reduced of and related oncology and primarily related U.S. in or impairment of a the benefit the offset loss largely In versus to by of loss of relates tax the rate income first, QX $XX.X with the XXXX $XXX,XXX performing. of ongoing $X.X recognized The or of in in license tax non-cash asset impact revenue per an $X.XX Revenues items $XXX.X resulting XXXX was million million. deferred a intangible recorded tax Gritstone QX, XXXX was QX were Arbutus' we services statements. XXXX. $X.XX revenues impairment million million, tax a a for agreement QX QX reversal reform. intangible The XXXX. which was loss share on So assets I’ll as of $XX.X of of impacted including deferred

on have Now expense $XX.X as to was the compared of million in we to and million and Sofia, This QX, development the at resulted continue Murray, $X.X a of repurchase in developing shares turning $X.X Symonds from a decrease includes steady QX, to to in flat Other described million pipeline, G&A income QX, nil to this and million expenses of rights a which result income our charges. of figure decreased expenses, stock-based us in value or increased non-cash contract compensation year collaborations a a XXXX. and exploration. consideration asset $XX.X total net was preclinical earlier in changes and in largely XXXX clinical QX by Dr. QX, foreign-currency invest research on prior, call. compared as is non-cash XXXX loss In merger, historically in income loss, of $X.X contingent Other income million XXXX. in fair interest consideration. to XXXX net issued

by the cash of Sciences. our have with position which XXXX and end completion million investments extended Roivant discuss strengthened around of I’ll $XXX.X runway the Finally, we and substantially strategic

burn. the closed During this the for our financing cash largely quarter, fourth This gross $XX offsets of we of proceeds first operating tranche million. XXXX

aggregate the $XXX $XXX.X XXXX. compared result, of XXXX, As at million we of a cash end had year-end the to of investments and end million balance at

started additional we the second a Following for including balance of of $XXX XXXX with January shareholder million. closed second we cash in of approval forma XXXX, tranche proceeds, pro a million. On Roivant’s proceeds basis, cash $XX.X the investment tranche

consolidation, fund to Roivant benefit entitlements efficiencies Mark. the With the back and close of from the turn Alnylam our XXXX. The expect summary, extend rate. to investment With current from beyond potential company the the call to I’ll cash side of from well our cash balance our over we further run royalty that potential our has future

Mark Murray

coming in I pipeline. its key a fourth continue to from year. closed today, value starting will Koert. believe while advance excellent quarter and We conclusion for In solid with the year position financial to that Arbutus Thanks, an I off our HBV this few shareholders a drive would to highlight like points

regulatory LNP could in of patisiran receiving for by year. royalty result product half approval XXXX, licensee payments Our its this which Alnylam the has second Arbutus projected

was for of please Thank start we joining the to and outstanding the you inhibitor XXXX Arbutus. for initiating our open Phase and Overall, for on pegylated HBV data of in of complete volunteers are tenofovir HBV this ARB-XXXX AB-XXX We and capsid enable look study human in the another the interim another half RNA treatment AB-XXX interferon. in X questions. year. you. year. And year mid-XXXX study of next-generation forward this from combination And lines novel filings Operator, our destabilize, We’ll by second DNA pivotal it we beyond. the plan regulatory to us first to studies year share

Operator

Katherine Thank a Instructions] do And question William with line we have from of the you. Xu [Operator Blair.

Katherine Xu

GalNAc that just I’m have? compared far, afternoon. to Good you the candidate to [ph] regards that is? So potent data Hi. you does from how wondering of does be had it potent and that XXXX, with to Mike, how so XXX how the compared

Mike Sofia

Well, that molecule. is potent I very will say XXX

look S-antigen work strong reported to very in one to together the things get think we differently. preclinical a log ECXX nanomolar its of of two we synergistically about seen very we I HBV work lines S-antigen have certainly models. S-antigen that is They think said, the technologies. one models We of all see But can greater models. compare these inhibition these reduction cell HBV in as we’ve animal production. maximal I hard at that in than in reduction in X.X production inhibition It's believe and overall we molecules that

is be very think potent in very AB-XXX. we’ve its any molecule again I actually upcoming GalNAc, safe not yet. but a of not We’ll some some our it we And data. So, to Relating date meeting, to scientific disclosed potent agent. disclosing say, will

Katherine Xu

Phase what from And Great. to this And patients of hurdle to LXXCC think study, still [ph] getting like generate it XXXX were need then previous X. combination the data do class monotherapy on to with interferon, you the you the you to the Do or plus new regard of intend that kind to combo? the be that seems couple new on triple then responders. in expect would

Mark Murray

XX system. It’s effects what in the on for terms So, study Katherine, in we’re patients in involving think expect pilot I immune this this the of study. study looking we a

and interferon in patients what We’ll other We happens which who lower. there the out S-antigen expect possible – off addition by what A molecular S-antigen be be if Of lot we’re past. after of some of to time over had definitely see to reduction would as system as S-antigen and should happens. we see and see coming different sustained outcome see S-antigen therapy. the loss course it accelerated to of good course down down to a drive doing we the testing levels see how re-waken lower immune

we’re in point to different your question possibilities what in open our then second the was? question, of you time me could remind this that generated. tells us data terms what as we at So And second

Katherine Xu

The LXXCC.

Mark Murray

Yes, intrigue so in by and again this study patients first again that we’re a some something group in something trial, we the scientifically will was of be small I make sense. evaluating of course that think can it

So this further looking in that we’ll at trial. be

Katherine Xu

Thanks.

Operator

our you. with of from [Indiscernible] next question line comes McCain the And Thank Keane

Unidentified Analyst

Yes. questions. Two

studies? guess from you for First, XXX. what and if interim might your or this XXX CTA point first those at file When we best see IND data

Mark Murray

regulatory year healthy anticipated first we So, a to of year to half of patients going and for year and first to going SAD/MAD certainly the by this on of in volunteers do then this end that molecule. data XXX plan half file the the end before HBV filing next into in the we we of have some should study

For XXX, data see first so in next should probably by of infected year, we this year, HBV sometime again mid half filing regulatory related in the patients.

Unidentified Analyst

us Hey, then that in date Acuitas to we’ve cut-off settlement the primary And what that Mark, great. remind XXXX? can agreement with improvements for maybe you made LNP with hope

Mark Murray

to Well, to of couple addition over the I continue think, of the generate And in Keith, and features lipids we’ve patents that issued years. platform. last on work different different more to we’ve continued

has that and couple from So, years RNA adapt That’s the to of larger years. RNA our last direction triggers focus of like in the really structures. the – the technology been our been kind last messenger work of for of sort generate has couple of interference to

Unidentified Analyst

Thanks Very for that. Okay. good.

Operator

Thank you.

Jefferies. of line Yee the with from comes question next Our Michael

Michael Yee

study progress XXXX, of that what convergent, the you efficacy to you Hep totally Congrats an at of that then at just questions. what the you afternoon. interim. and for what guys. figure and just you’re XXX? interim? be what as second I results, you for alluded on on least Two looking is defines far. wanted question Is actually be developing can are for thinking to then inhibitor but the there you have success so sort in Good B if capsid the think would fine of me on tell is looking zero “responder” the like the get you and lot Thanks. things, to there interim would XX Hey, is program, all pause. how about combination going confirm, compare some or patients was just you able want it to And an about to on go One

Bill Symonds

Symonds. Bill It’s Mike. Hi,

reduction you be a first certain or far in -- time leads study, to goes as is also on surface responder to B a and as be combination not, results, threshold. we basically below where that point interim receive interferon from the talking what certain the demonstrate to a the So would there basically which to someone of six week considered to non-responder have results decided patient have about responder, period we’re antigen hepatitis the level

have So ability also they got the number to and demonstrate they to get their S-antigen. below to certain a drop then

patients what the expect interim who And DNA terms then be and depends probably B HBV again, that can will the the starting patient it So levels see surface seeing things course, you in with terms know you we of would be antigen two you either there of a those imagine would main definition is results of And there. we’d be of at in fall, start where someone logs be to parameters. of responder. looking of but will the in hepatitis the

that’s over about levels. in where time So, loss seeing see XX-weeks think wouldn’t these think much, you time, at but to in expect I can period, S-antigen the much that lower six-week I

Michael Yee

of to S-antigen, you the be could reductions clear, see you could of have XX potential end of I and just conversion, DNA So weeks, people who not? complete at mean, share

Bill Symonds

quite if a had yes, those year hepatitis the mean, absolute study that I training patients. level patients antigen B at of recall could, XX-week last you number after below very you the who could, we surface low, X of had from XXX actually Phase we run period well You in that

push the such what when of bit that little and with given additional regimen them interferon concept add try thinking boost the more we to lower that’s us is as a even just that gives an that. and So something like patients to that

Michael Yee

-- And okay. then just you the remove Okay.

Mark Murray

and stop sustaining So, continued for response. of treatment we’ll yes, the everything at XX-week off look then initial so will

Michael Yee

capsid. on Then Okay.

Mark Murray

we we’ve XXX With the progress on believe rapid Mike alluded to think essentially XXX, that I earlier, capsid, respect ready very proof-of-concept think in a and humans clinical we and to of better have comparison made use to we already forward XXX top cap as in our use it’s better – of just of sorry, then XXX, and the it’s think capital a sort two between of just make move we them. I’m our a of to getting

Michael Yee

clear But you have and patients, reductions correct, to DNA XXX? RNA be don’t in in

Mark Murray

Correct.

Michael Yee

Yes. that no you When see we want just just feel like to to go or need to XXX?

Mark Murray

I think we believe of that that XXX knows is one, going to the we are pretty going much and field be these in molecules certain superior, what feel capsid number do we potencies.

So think comparison. it��s we make to don’t necessary that to do the

Michael Yee

Thanks. Got it. Okay.

Mark Murray

Okay.

Operator

David next Thank of you. And Burton. Martin Bloom line from question comes with our the

Unidentified Analyst

Hi. Antonio on Dave. [ph] This for line is

So is… my question

Mark Murray

I’m didn’t sorry your I get name?

Unidentified Analyst

for line on Antonio, Hi. Dave.

Mark Murray

afternoon. Good

Unidentified Analyst

afternoon. Good

combo you based is patients would for to as to first question peg all my interferon suppose cures wondering see responder design the of ARB just Phase study response and of in which what related X ARB only entrance more enable the to So I’m the efficacy? functional rationale is whether testing other

Mark Murray

I’d happy that. to be Sure. answer

interferon tend a first to the level with patients loss. typically antigen achieving So would a basically that data is there is showing of we that have therapy surface to of lower who S-antigen B the out lot probability XXXX want S-antigen concept down hepatitis higher there drive a because below levels start

better a basically at S-antigen the shot we’re ARB-XXXX to So using to working. them down interferon get drive

way patients in think best at that creating use and the about of to is the this XXXX respond basically group we likely think to who in interferon more a how with are combination time. point So to

interferon we that who into patients initial if a don't to the it's XXXX in that feel the six had and really as haven't in point time response putting respond we they an [ph]. to With patient don't well with weeks trial nuc worth, initial ARB-XXXX at

Unidentified Analyst

earlier to seen And What have won't That’s your of delivery I issues that and related second into gives question in GalNAc? confidence you other that the Okay. program. my visions then run just you of safety of the with some your GalNAc helpful. is

Mark Murray

and that effective do Well, very this and I at in extensive pretty it’s preclinical so a mean safety animal we know multiple model been so certainly of a animal and sort point we this in models modules forth, safe agents. assessment

So time to I of comfortable think safety forward. with at and move we’re feel molecule profile ready point in the this this very

Unidentified Analyst

All right. Thank you.

Operator

from line And of Bayko our next question Lisa with the comes JMP Securities.

Lisa Bayko

Hi.

loss response. are to and Mike reduction constitute question, I What would think follow-up a you certain S-antigen those levels a about, are said DNA you defined? of talking Just level

Mark Murray

We haven’t patients not disclose a DNA. below threshold certain publicly, but hepatitis antigen, that the to also and want of basically level reduction antigen surface same was we surface in at B it be

ability S-antigen So presence get a you to to below threshold a have to is demonstrate responder. denote drop the the XXXX in of and who certain then patient a

Lisa Bayko

care? different Or And responders that… Okay. the functional toward is getting

Mark Murray

Correct.

Lisa Bayko

Okay.

Mark Murray

more quite think are This identifying shot is just a of out is there we a to where people down being who there. on and getting at better effective S-antigen literature interferon level has that below a certain bit level

Lisa Bayko

Okay.

place do will kind the have then what do new you off kind starting Okay. to to of And those in – as RNA your capsid of to you you in mean, get pieces that to inhibitor it think be stable I of and do formulate all is vision place. that think of the about fit where how out those would or care? you kind your how overall profile of interferon into kind or trying the functional getting RNAi, overall fit potentially into to I’m lose those just figure

Mark Murray

Lisa, Well, is this Mark.

here. to – going do I need you’re that things long think for multiple believe to we I we’ve think time said obviously

or immune the then of reactivate. First the activate and system virus patient’s cripple to all allow

address. address elements I that what we been molecule to So, have think things possibilities using RNA like interference the to XXX represent XXX viral up small are and to

we it may term drive S-antigen those about very see to So agents study how and of that. that I immune works. alone DNA think if then learn our that the here very is can consider low will has portion near And term HBV focus down combination we have described we use medium reactivation focus to in And or levels. to to and Bill the something important from

Lisa Bayko

Thanks. Okay.

Operator

comes question from Kumar from the next our And you. Riley of B. FBR. Thank Madhu line

Madhu Kumar

morning, good my for taking Thanks Hey, questions. guys.

short your Phase the you So, is with reduction to what dosing? one amount sufficient study, discussing about do sufficient or what is kind this about is what as of log log, combination visibility of experts question be we interference this earlier S-antigen S-antigen really interferon, kind in discussed predictive serve X have of [ph] a to in think of half term

Mark Murray

Sure.

population think outcome a consistently off XXX interferon a some data with what of a number I start and seen that’s lower time bit starting really to of a etcetera, studies that use show point they data below loss. And of actually S-antigen bit have S-antigen investigated show in I and starting of sites is. think instance XXXX, There’s a S-antigen this. at of typically a the that at the patients in been years have quite likelihood a who quite achieving typically published I looking levels of between but out different correlations that Asia in cut there’s for of XXX, over levels patients start where better XXXX of then

interferon drive study part of time. period you the is of around XXXX to So use after to design then really that’s the thinking down and kind start S-antigen the of of can a this

Madhu Kumar

level? So, reduction the not surface a to relative antigen there’s patient's baseline reduction an absolute

Mark Murray

Yes.

accounts So both below you that and you drop want the some have they when logs, of number kind it least seven so depending have people cut patient logs level, or have show -- a to up a got six they say three get sure has you've as We by start got so of the to could that you where I patients at so, both, make have come either of show have coming to because demonstrate they can to S-antigen down mean, certain and there. to off of those responsive. have are situations for logs then S-antigen to to patient

Madhu Kumar

Okay. you. Thank That’s all my questions.

Operator

Tolmie session Tiffany today. Instructions]. you. any turn to the our question comments. and [Operator to like Thank that over And for back I’d call concludes answer for closing

Tiffany Tolmie

you everyone. participation concludes appreciate the and our with today. We call on updates forward operator. months sharing ahead. This today progress you, look Thank Thank we in our on you to your the call

Operator

and participation and Everyone Ladies thank a day. gentlemen, disconnect. does for may have you And you today’s the you. in program great Thank conclude this now your conference.

Arbutus Biopharma (ABUS) 14 Mar 182017 Q4 Earnings call transcript